References
1. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci . 2019;20(9):2288. doi:10.3390/ijms20092288
2. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med . 2005;352(11):1112-1120. doi:10.1056/NEJMra041867
3. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM: An International Journal of Medicine . 2003;96(9):635-642. doi:10.1093/qjmed/hcg109
4. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J . 2013;13(4):533-540.
5. Maitland S, Baker M. Serotonin syndrome. Drug Ther Bull . 2022;60(6):88-91. doi:10.1136/dtb.2021.000032
6. Dvir Y, Smallwood P. Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry . 2008;30(3):284-287. doi:10.1016/j.genhosppsych.2007.09.007
7. Dumuis A, Sebben M, Bockaert J. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. Mol Pharmacol . 1988;33(2):178-186.
8. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ . 2014;348:g1626. doi:10.1136/bmj.g1626
9. Gillman PK. A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action. Biological Psychiatry . 2006;59(11):1046-1051. doi:10.1016/j.biopsych.2005.11.016
10. Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res . 2001;890(1):23-31. doi:10.1016/s0006-8993(00)03020-1
11. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. Int J Tryptophan Res . 2019;12:1178646919873925. doi:10.1177/1178646919873925
12. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-85. doi: 10.1081/clt-120037428. PMID: 15362595.
13. Simon LV, Keenaghan M. Serotonin Syndrome. In: StatPearls . StatPearls Publishing; 2022. Accessed February 17, 2023. http://www.ncbi.nlm.nih.gov/books/NBK482377/
14. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry . 2014;75(2):169-177. doi:10.4088/JCP.13m08443
15. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) . 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001
16. Spadaro A, Scott KR, Koyfman A, Long B. High risk and low prevalence diseases: Serotonin syndrome. Am J Emerg Med . 2022;61:90-97. doi:10.1016/j.ajem.2022.08.030
17. Racz R, Soldatos TG, Jackson D, Burkhart K. Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis. Clin Transl Sci . 2018;11(3):322-329. doi:10.1111/cts.12543
18. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry . 2002;47(1):27-38.
19. Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J . 2014;13:1163-1191.
20. Nagamine T. Neuroleptic Malignant Syndrome or Serotonin Syndrome?Psychiatr Danub . 2022;34(3):526-527.
21. Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 13th ed. Wiley-Blackwell 2018: 337.
22. Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database. J Clin Psychopharmacol . 2015;35(4):382-388. doi:10.1097/JCP.0000000000000344
23. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother . 2004;38(3):411-413. doi:10.1345/aph.1D344
24. Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord . 2018;20(1):17r02185. doi:10.4088/PCC.17r02185
25. Kapur S, Zipursky RB, Jones C, Wilson AA, DaSilva JD, Houle S. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry . 1997;154(6):884. doi:10.1176/ajp.154.6.884a
26. Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr . 2019;42(2):56-61. doi:10.18773/austprescr.2019.014